Gilead Sciences Research Scholars Cystic Fibrosis Program Open to Applications

Gilead Sciences is a biopharmaceutical company with operations in North America, Europe and Australia. The company researches, develops and commercialises innovative therapeutics with the aim of advancing the care of patients with life-threatening diseases.

The Gilead Science Research Scholars Cystic Fibrosis Program is designed to support basic, translational, and clinical research in the field of cystic fibrosis (CF). Areas of research may include, but are not limited to:

CF basic pathophysiology

CF-specific microbiology

CF-related epidemiology, clinical care, and health-related outcomes

The programme is open to applicants from Canada, Europe and the United States. European applicants must hold a medical degree or PhD, and anticipate receiving a faculty appointment or an assistant professorship within three years, in association with a research institution in one of the eligible regions/countries. Applicants must also have a strong career interest in cystic fibrosis.

Financial support is provided to three junior faculty researchers for a two-year period. Each award is funded up to US$130,000, to be paid in annual installments of up to US$65,000 per year for two years.

The deadline for applications is 9 August 2019 (11:59 Eastern Daylight Time).

Applicants will be notified in September 2019.

More information about this research funding opportunity and the application process is available on the RESEARCHconnect funding information platform. RESEARCHconnect provides up-to-the minute content, insight and analysis on research funding news and policy. To find out more about how RESEARCHconnect can keep you in the know, and subscription fees, contact us today.